Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo

Journal of Molecular Biology

Volumn 407, Issue 2, 2011, Pages 298-315

  Lindborg, M ^a   Cortez, E ^b   Hoiden Guthenberg I ^a   Gunneriusson, E ^a   Von Hage, E ^a   Syud, F ^c   Morrison, M ^d   Abrahmsen L ^a,g   Herne, N ^a,f   Pietras, K ^b   Frejd, F Y ^a,e  

^a Affibody AB   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GE GLOBAL RESEARCH   (United States)

^d GE HEALTHCARE   (United Kingdom)

^e UPPSALA UNIVERSITY   (Sweden)

^f NeuroNova AB   (Sweden)

^g Algeta ASA   (Norway)

Author keywords

Affibody molecule; affinity maturation; PDGFR; stroma targeting; tumor targeting

Indexed keywords

AFFIBODY PROTEIN; BINDING PROTEIN; FC RECEPTOR; IMMUNOGLOBULIN G; OLIGONUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; Z02465 PROTEIN; Z02483 PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DOT HYBRIDIZATION; ENDOTHELIUM; HEATING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INSULINOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN ISOLATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR VASCULARIZATION;

MURINAE; SUS;

EID: 79952313111     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.01.033     Document Type: Article

References (50)

1. Joyce J.A. Therapeutic targeting of the tumor microenvironment Cancer Cell 7 2005 513 520 (Pubitemid 40799245)
2. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis Nat. Rev. Cancer 9 2009 239 252
3. Carmeliet P. Angiogenesis in health and disease Nat. Med. 9 2003 653 660 (Pubitemid 36749213)
4. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
5. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat. Rev. Drug Discov. 3 2004 391 400 (Pubitemid 38618122)
6. Kaspar M., Zardi L., and Neri D. Fibronectin as target for tumor therapy Int. J. Cancer 118 2006 1331 1339
7. Neri D., and Bicknell R. Tumour vascular targeting Nat. Rev. Cancer 5 2005 436 446 (Pubitemid 40791486)
8. Siemann D.W., Chaplin D.J., and Walicke P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin. Invest. Drugs 18 2009 189 197
9. Heldin C.H., Eriksson U., and Ostman A. New members of the platelet-derived growth factor family of mitogens Arch. Biochem. Biophys. 398 2002 284 290 (Pubitemid 34848597)
10. Ostman A., and Heldin C.H. PDGF receptors as targets in tumor treatment Adv. Cancer Res. 97 2007 247 274 (Pubitemid 46528991)
11. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma Cytokine Growth Factor Rev. 15 2004 275 286 (Pubitemid 38781051)
12. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R.K., Heldin C.H., and Rubin K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res. 61 2001 2929 2934 (Pubitemid 32691937)
13. Rodt S.A., Ahlen K., Berg A., Rubin K., and Reed R.K. A novel physiological function for platelet-derived growth factor-BB in rat dermis J. Physiol. 495 1996 193 200 (Pubitemid 26288464)
14. Baranowska-Kortylewicz J., Abe M., Pietras K., Kortylewicz Z.P., Kurizaki T., and Nearman J. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy Cancer Res. 65 2005 7824 7831 (Pubitemid 41297258)
15. Pietras K., Rubin K., Sjoblom T., Buchdunger E., Sjoquist M., Heldin C.H., and Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy Cancer Res. 62 2002 5476 5484
16. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors J. Clin. Invest. 111 2003 1287 1295 (Pubitemid 36554699)
17. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., and Hammes H.P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J. 18 2004 338 340
18. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J. Clin. Oncol. 23 2005 939 952 (Pubitemid 46202314)
19. Paulsson J., Sjoblom T., Micke P., Ponten F., Landberg G., and Heldin C.H. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer Am. J. Pathol. 175 2009 334 341
20. Thorarinsdottir H.K., Santi M., McCarter R., Rushing E.J., Cornelison R., Jales A., and MacDonald T.J. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas Clin. Cancer Res. 14 2008 3386 3394
21. Schmidt M.M., and Wittrup K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther. 8 2009 2861 2871
22. Ahlgren S., Wallberg H., Tran T.A., Widstrom C., Hjertman M., and Abrahmsen L. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine J. Nucl. Med. 50 2009 781 789
23. Nilsson F.Y., and Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy Curr. Opin. Drug Discov. Dev. 10 2007 167 175 (Pubitemid 46438646)
24. Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., and Hoiden-Guthenberg I. Tumor imaging using a picomolar affinity HER2 binding affibody molecule Cancer Res. 66 2006 4339 4348
25. 68Ga-labeled affibody molecules J. Nucl. Med. 51 2010 892 897
26. 177Lu-labeled HER2-specific Affibody molecule Cancer Res. 67 2007 2773 2782 (Pubitemid 46548966)
27. Zielinski R., Lyakhov I., Jacobs A., Chertov O., Kramer-Marek G., and Francella N. Affitoxin-a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors J. Immunother. 32 2009 817 825
28. Lofblom J., Feldwisch J., Tolmachev V., Carlsson J., Stahl S., and Frejd F.Y. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications FEBS Lett. 584 2010 2670 2680
29. Feldwisch J., Tolmachev V., Lendel C., Herne N., Sjoberg A., and Larsson B. Design of an optimized scaffold for affibody molecules J. Mol. Biol. 398 2010 232 247
30. Nord K., Gunneriusson E., Ringdahl J., Stahl S., Uhlen M., and Nygren P.A. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain Nat. Biotechnol. 15 1997 772 777 (Pubitemid 27329481)
31. Ekerljung L., Lindborg M., Gedda L., Frejd F.Y., Carlsson J., and Lennartsson J. Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line Biochem. Biophys. Res. Commun. 377 2008 489 494
32. Jonsson A., Wallberg H., Herne N., Stahl S., and Frejd F.Y. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro Biotechnol. Appl. Biochem. 54 2009 93 103
33. Tolmachev V., Friedman M., Sandstrom M., Eriksson T.L., Rosik D., and Hodik M. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry J. Nucl. Med. 50 2009 274 283
34. Friedman M., Lindstrom S., Ekerljung L., Andersson-Svahn H., Carlsson J., and Brismar H. Engineering and characterization of a bispecific HER2 × EGFR-binding affibody molecule Biotechnol. Appl. Biochem. 54 2009 121 131
35. Kramer-Marek G., Kiesewetter D.O., and Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules J. Nucl. Med. 50 2009 1131 1139
36. 18F]fluorobenzaldehyde via oxime chemistry Mol. Imaging Biol. 10 2008 177 181
37. Tolmachev V., Mume E., Sjoberg S., Frejd F.Y., and Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules Eur. J. Nucl. Med. Mol. Imaging 36 2009 692 701
38. Lee S.B., Hassan M., Fisher R., Chertov O., Chernomordik V., and Kramer-Marek G. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging Clin. Cancer Res. 14 2008 3840 3849
39. Friedman M., Orlova A., Johansson E., Eriksson T.L., Hoiden-Guthenberg I., and Tolmachev V. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule J. Mol. Biol. 376 2008 1388 1402
40. Wahlberg E., Lendel C., Helgstrand M., Allard P., Dincbas-Renqvist V., and Hedqvist A. An affibody in complex with a target protein: structure and coupled folding Proc. Natl Acad. Sci. USA 100 2003 3185 3190 (Pubitemid 36358200)
41. 2: separation of affinity from specificity Mol. Immunol. 30 1993 1279 1285
42. Shen J., Vil M.D., Prewett M., Damoci C., Zhang H., and Li H. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody Neoplasia 11 2009 594 604
43. Shen J., Vil M.D., Zhang H., Tonra J.R., Rong L.L., and Damoci C. An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody Biochem. Biophys. Res. Commun. 357 2007 1142 1147 (Pubitemid 46693690)
44. Jayson G.C., Parker G.J., Mullamitha S., Valle J.W., Saunders M., and L. Broughton Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume J. Clin. Oncol. 23 2005 973 981 (Pubitemid 46202317)
45. Ruther U. pUR 250 allows rapid chemical sequencing of both DNA strands of its inserts Nucleic Acids Res. 10 1982 5765 5772
46. Gronwall C., Jonsson A., Lindstrom S., Gunneriusson E., Stahl S., and Herne N. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides J. Biotechnol. 128 2007 162 183 (Pubitemid 44960520)
47. Arora P., Oas T.G., and Myers J.K. Fast and faster: a designed variant of the B-domain of protein A folds in 3 microsec Protein Sci. 13 2004 847 853 (Pubitemid 38429208)
48. Orlova A., Tolmachev V., Pehrson R., Lindborg M., Tran T., and Sandstrom M. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors Cancer Res. 67 2007 2178 2186 (Pubitemid 46424237)
49. Gunneriusson E., Nord K., Uhlen M., and Nygren P. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling Protein Eng. 12 1999 873 878 (Pubitemid 29533112)
50. Westermark B., Siegbahn A., Heldin C.H., and Claesson-Welsh L. B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase Proc. Natl Acad. Sci. USA 87 1990 128 132